RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Spinocerebellar Ataxia: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
CAG repeat length shapes bidirectional functional connectome alterations in spinocerebellar ataxia type 3: a multimodal MRI study.
Yang Xianfei et al., Neuroscience (18 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42893779/
- 2.
First Reported Coexistence of Acetylcholine Receptor-Positive Myasthenia Gravis and Genetically Confirmed Spinocerebellar Ataxia Type 6
Jawad Abou Zeid et al., Cureus (17 October 2026)
https://doi.org/10.7759/cureus.118085
- 3.
Stage-Specific Patterns of Imaging and Non-Motor Biomarkers in Spinocerebellar Ataxia Type 3.
Li Chun et al., Annals of clinical and translational neurology (13 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42867110/
- 4.
Autophagosome-tethering compounds selectively lower mutant ataxin-3 in preclinical models of spinocerebellar ataxia type 3
Hongyu Yuan et al., bioRxiv (Cold Spring Harbor Laboratory) (4 October 2026)
https://doi.org/10.64898/2026.10.02.756117
- 5.
Clinical insights from the diagnosis of spinocerebellar ataxia in young Ghanaians: a case series
Walter Appati et al., BMC Neurology (1 October 2026)
https://doi.org/10.1186/s12883-026-05427-x
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
NCT06672445 · Active (not recruiting) · Phase 1 · Arrowhead Pharmaceuticals
Ages 18 to 65
https://clinicaltrials.gov/study/NCT06672445
- 2.
STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
NCT05490563 · TERMINATED · Phase 2 / Phase 3 · Seelos Therapeutics, Inc.
Ages 18 to 75
https://clinicaltrials.gov/study/NCT05490563
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Spinocerebellar Ataxia
Spinocerebellar Ataxia refers to a group of inherited progressive neurological disorders characterised by degeneration of the cerebellum and its connections, causing difficulty walking, poor coordination, and speech problems. More than 40 genetic subtypes have been identified. There is currently no disease-modifying treatment, but active clinical trials are under way.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
The ATXN3 gene is the primary driver of brain damage in spinocerebellar ataxia type 3 (SCA3). We aimed to elucidate the patterns of connectome alterations shaped by cytosine-adenine-guanine (CAG) repeat length in SCA3. Eighty-nine genetically confirmed patients with SCA3 and 89 age-, sex-, education-matched healthy controls underwent multimodal MRI and comprehensive clinical assessments. Connectome-based predictive modeling (CPM) was used to identify functional connectivity patterns associated with CAG repeat length. Structural brain damage was assessed using voxel-based morphometry. Mediation analysis was performed to examine the role of structural impairment in connectivity changes. CPM identified a positive and a negative network, whose connectivity strength increased or decreased with CAG repeat length. The positive network (r = 0.397, P < 0.001) was mainly localized within the cerebello-motor circuit and was positively associated with ataxia severity and functional disability. The negative network (r = 0.243, P = 0.022) was distributed across large-scale networks, with selective vulnerability of interhemispheric connectivity, and was associated with motor dysfunction. Besides the canonical motor pathways, limbic-related connectivity was related to motor impairment. Structural analyses revealed widespread gray matter atrophy centered on the cerebellum. Cerebellar atrophy statistically mediated the association between CAG repeat length and connectivity decreases. CAG repeat length is associated with a bidirectional connectopathy in SCA3. Cerebellar atrophy may mediate the connectivity decreases. Future longitudinal studies are required to examine the underlying causal pathway.
Common Questions
What is Spinocerebellar Ataxia?
Spinocerebellar Ataxia refers to a group of inherited progressive neurological disorders characterised by degeneration of the cerebellum and its connections, causing difficulty walking, poor coordination, and speech problems. More than 40 genetic subtypes have been identified. There is currently no disease-modifying treatment, but active clinical trials are under way.
How many clinical trials are available for Spinocerebellar Ataxia?
RareWays currently indexes 72 clinical trials for Spinocerebellar Ataxia, of which 10 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Spinocerebellar Ataxia come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Spinocerebellar Ataxia.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.